



(19) Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 601 618 A2

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 93203045.5

(51) Int. Cl.5: A61K 47/48, A61K 9/51,
A61K 49/04

(22) Date of filing: 30.10.93

(30) Priority: 11.12.92 US 989281

Patent Department,
90 Park Avenue
New York, New York 10016(US)
Inventor: Rajagopalan,Natarajan,c/o Sterling
Winthrop Inc.
Patent Department,
90 Park Avenue
New York, New York 10016(US)

(43) Date of publication of application:
15.06.94 Bulletin 94/24

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE

(71) Applicant: STERLING WINTHROP INC.
90 Park Avenue
New York, NY 10016(US)


(72) Inventor: Na, George C., c/o Sterling Winthrop
Inc.

(74) Representative: Haile, Helen Cynthia et al
Kodak Limited
Patent Department
Headstone Drive
Harrow, Middlesex HA1 4TY (GB)

(54) Use of charged phospholipids for decreasing nanoparticulate aggregation.

(57) A composition comprising nanoparticles having a non-ionic surfactant as a surface modifier adsorbed on the surface thereof and a charged phospholipid as a cloud point modifier associated therewith, which cloud point modifier is present in an amount sufficient to increase the cloud point of the surface modifier and methods of making such nanoparticles are described. A preferred non-ionic surfactant is a poloxamine or tyloxapol, and a preferred cloud point modifier is dimyristoyl phosphatidyl glycerol.

FIG. 1



EP 0 601 618 A2

FIELD OF THE INVENTION

This invention relates to therapeutic and diagnostic compositions with a modified cloud point, and to a method for the preparation thereof.

5

BACKGROUND OF THE INVENTION

Nanoparticles, described in U.S. Patent No. 5,145,684, are particles consisting of a poorly soluble therapeutic or diagnostic agent onto which are adsorbed a non-crosslinked surface modifier, and which have 10 an average particle size of less than about 400 nanometers (nm).

As a result of their small size, sterilization of therapeutic and diagnostic agents in nanoparticulate form stabilized by a surface modifier (surfactant) is difficult. Filtration using a filter of 0.22 μm mesh size is sufficient to remove most bacteria and viruses, but the nanoparticles, due to their sizes, cannot be sterile filtered. Conventional autoclaving (steam heat) at 121 °C will result in substantial aggregation and/or growth 15 of particle size, rendering the resulting particles unusable.

The aggregation of nanoparticles upon heating is directly related to the precipitation and/or phase separation of the surface modifier (surfactant) at temperatures above the cloud point of the surfactant where the bound surfactant molecules are likely to dissociate from the nanoparticles and precipitate and/or phase separate, leaving the nanoparticles unprotected. The unprotected nanoparticles can then aggregate into 20 clusters of particles. Upon cooling, the surfactant redissolves into the solution, which then coats the aggregated particles and prevent them from dissociating into smaller ones as shown in Figure 1.

This invention is directed to novel compositions that allow autoclaving of nanoparticles with reduced or no particle size growth. These compositions provide for a modification of the cloud point of the surface modifier in the composition such that the nanoparticles do not agglomerate during autoclaving. This 25 invention is also directed to a method of making such compositions.

BRIEF SUMMARY OF THE INVENTION

According to the present invention therefore there is provided a composition comprising nanoparticles 30 having a non-ionic surfactant as a surface modifier adsorbed on the surface thereof and a charged phospholipid as a cloud point modifier associated therewith, which cloud point modifier is present in an amount sufficient to increase the cloud point of the surface modifier. In a preferred embodiment, the cloud point of the non-ionic surfactant is increased above the sterilization, e.g. autoclaving, temperature of the nanoparticles to prevent agglomeration.

In a further aspect the invention provides a method of making nanoparticles having a non-ionic surfactant as a surface modifier adsorbed on the surface thereof and a charged phospholipid as a cloud 35 point modifier associated therewith, said method comprising contacting said nanoparticles with the cloud point modifier for a time and under conditions sufficient to increase the cloud point of the non-ionic surfactant.

40

BRIEF DESCRIPTION OF THE FIGURE

Fig. 1 is a graph showing the aggregation of nanoparticles comprising 20% of the ethyl ester of diatrazoic acid and the surface modifier Tetronic 908 (T908) upon autoclaving at 120 °C. Samples of the 45 autoclaved nanoparticles were removed at various times after autoclaving, and the average particle size (Z average) was determined for each time point.

DETAILED DESCRIPTION OF THE INVENTION

The nanoparticles useful in the practice of this invention as hereinbefore defined include a non-ionic 50 surface modifier. Surface modifiers useful herein physically adhere to the surface of the therapeutic or diagnostic agent but do not chemically react with the agent or themselves. Individually adsorbed molecules of the surface modifier are essentially free of intermolecular crosslinkages. Preferred surface modifiers can be selected from known non-ionic surfactants, including the poloxamines such as Tetronic™ 908 (also 55 known as Poloxamine 908), which is a tetrafunctional block copolymer derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine, available from BASF, or Tetronic 1508 (T-1508), or a polymer of the alkyl aryl polyether alcohol type, such as tyloxapol.

The surface modifiers are commercially available and/or can be prepared by techniques known in the art. Two or more surface modifiers can be used in combination.

5 The nanoparticles useful in the practice of this invention can be prepared according to the methods disclosed in U.S. Patent No. 5,145,684. Briefly, nanoparticles are prepared by dispersing a poorly soluble therapeutic or diagnostic agent in a liquid dispersion medium and wet-grinding the agent in the presence of grinding media to reduce the particle size of the contrast agent to an effective average particle size of less than about 400 nm. The particles can be reduced in size in the presence of a surface modifier e.g during the wet grinding process.

10 A general procedure for preparing the particles useful in the practice of this invention follows. The therapeutic or diagnostic agent selected is obtained commercially and/or prepared by techniques known in the art as described above, in a conventional coarse form. It is preferred, but not essential, that the particle size of the coarse therapeutic or diagnostic substance selected be less than about 100 μm as determined by sieve analysis. If the coarse particle size of that agent is greater than about 100 μm , then it is preferred that the coarse particles of the therapeutic or diagnostic agent be reduced in size to less than 100 μm using a conventional milling method such as airjet or fragmentation milling.

15 The coarse therapeutic or diagnostic agent selected can then be added to a liquid medium in which it is essentially insoluble to form a premix. The concentration of the therapeutic or diagnostic agent in the liquid medium can vary from about 0.1-60%, and preferably is from 5-30% (w/w). It is preferred, but not essential, that the surface modifier be present in the premix. The concentration of the surface modifier can vary from about 0.1 to 90%, and preferably is 1-75%, more preferably 10-60% and most preferably 10-30% by weight based on the total combined weight of the drug substance and surface modifier. The apparent viscosity of the premix suspension is preferably less than about 1000 centipoise.

20 The premix can be used directly by wet grinding to reduce the average particle size in the dispersion to less than 400 nm. It is preferred that the premix be used directly when a ball mill is used for attrition. Alternatively, the therapeutic or diagnostic agent and, optionally, the surface modifier, can be dispersed in the liquid medium using suitable agitation, e.g. a roller mill or a Cowles type mixer, until a homogeneous dispersion is observed in which there are no large agglomerates visible to the naked eye. It is preferred that the premix be subjected to such a premilling dispersion step when a recirculating media mill is used for attrition.

25 30 Wet grinding can take place in any suitable dispersion mill, including, for example, a ball mill, an attritor mill, a vibratory mill, and media mills such as a sand mill and a bead mill. A media mill is preferred due to the relatively shorter milling time required to provide the intended result, i.e. the desired reduction in particle size. For media milling, the apparent viscosity of the premix preferably is from about 100 to about 1000 centipoise. For ball milling, the apparent viscosity of the premix preferably is from about 1 up to about 100 centipoise. Such ranges tend to afford an optimal balance between efficient particle fragmentation and media erosion.

35 40 The grinding media for the particle size reduction step can be selected from rigid media preferably spherical or particulate in form having an average size less than about 3 mm and, more preferably, less than about 1 mm. Such media desirably can provide the particles of the invention with shorter processing times and impart less wear to the milling equipment. The selection of material for the grinding media is not believed to be critical. However, preferred media have a density greater than about 3 g/cm³. Zirconium oxide, such as 95% ZrO₂ stabilized with magnesia, zirconium silicate, and glass grinding media provide particles having levels of contamination which are believed to be acceptable for the preparation of therapeutic or diagnostic compositions. However, other media, such as stainless steel, titania, alumina, and 45 95% ZrO₂ stabilized with yttrium, are believed to be useful.

45 50 The attrition time can vary widely and depends primarily upon the particular wet grinding mill selected. For ball mills, processing times of up to five days or longer may be required. On the other hand, processing times of less than 1 day (residence times of about one minute up to several hours) have provided the desired results using a high shear media mill.

55 The particles must be reduced in size at a temperature which does not significantly degrade the therapeutic or diagnostic agent. Processing temperatures of less than about 30-40 °C are ordinarily preferred. If desired, the processing equipment can be cooled with conventional cooling equipment. The method is conveniently carried out under conditions of ambient temperature and at processing pressures which are safe and effective for the milling process. For example, ambient processing pressures are typical of ball mills, attritor mills and vibratory mills. Processing pressures up to about 140 kPa (approx. 20 psi) are typical of media milling.

The surface modifier, if not present in the premix, must be added to the dispersion after attrition in an amount as described for the premix. Thereafter, the dispersion can be mixed, e.g. by shaking vigorously.

Optionally, the dispersion can be subjected to a sonication step, e.g. using an ultrasonic power supply. For example, the dispersion can be subjected to ultrasonic energy having a frequency of 20-80 kHz for a time of about 1 to 120 seconds.

The relative amount of therapeutic or diagnostic agent and surface modifier can vary widely and the optimal amount of the surface modifier can depend, for example, upon the particular therapeutic or diagnostic agent and surface modifier selected, the critical micelle concentration of the surface modifier if it forms micelles, the hydrophilic lipophilic balance (HLB) of the stabilizer, the melting point of the stabilizer, its water solubility, the surface tension of water solutions of the stabilizer, etc. The surface modifier preferably is present in an amount of about 0.1-10 mg/m² surface area of the therapeutic or diagnostic agent. The surface modifier can be present in an amount of 0.1-90%, preferably 1-75%, more preferably 10-60%, and most preferably 10-30% by weight based on the total weight of the dry particle.

Therapeutic and diagnostic agents useful in the composition of the present invention include those disclosed in U.S. Patent No. 5,145,684, and published European specification EP-A-0 498,482. A preferred diagnostic agent is the x-ray imaging agent ethyl 3,5-diacetoamido-2,4,6-triiodobenzoate, the ethyl ester of diatrazoic acid.

As used herein, particle size refers to a mean particle size as measured by conventional particle size measuring techniques well known to those skilled in the art, such as sedimentation field flow fractionation, photon correlation spectroscopy, or disk centrifugation. By "an effective average particle size of less than about 400 nm" it is meant that at least 90% of the particles have a particle size of less than about 400 nm when measured by the above-noted techniques. In preferred embodiments of the invention, the effective average particle size is less than about 300 nm, and more preferably less than about 250 nm. In some embodiments of the invention, an effective average particle size of less than about 200 nm has been achieved. With reference to the effective average particle size, it is preferred that at least 95% and, more preferably, at least 99% of the particles have a particle size less than the effective average, e.g. 400 nm. In particularly preferred embodiments, essentially all of the particles have a size less than 400 nm. In some embodiments, essentially all of the particles have a size less than 250 nm.

A method for the preparation of a nanoparticle composition according to this invention includes the steps of introducing a therapeutic or diagnostic agent, a liquid medium, grinding media, and optionally, a surface modifier into a grinding vessel; wet grinding to reduce the particle size of the therapeutic or diagnostic agent to less than about 400 nm; and separating the particles and optionally the liquid medium from the grinding vessel and grinding media, for example, by suction, filtration or evaporation. If the surface modifier is not present during wet grinding, it can be admixed with the particles thereafter. The liquid medium, most often water, can serve as the pharmaceutically acceptable carrier. The method preferably is carried out under aseptic conditions. Thereafter, the nanoparticle composition preferably is subjected to a sterilization process.

As noted elsewhere herein, sterile filtration will not provide adequate sterilization for nano-particles. Therefore, other methods of sterilization are required. For example, steam or moist heat sterilization at temperatures of about 121 °C for a time period of about 15 minutes can be used. At altitudes near sea level, such conditions are attained by using steam at a pressure of about 100 kPa (approx. 15 psi) in excess of atmospheric pressure.

Dry heat sterilization may also be performed, although the temperatures used for dry heat sterilization are typically 160 °C for time periods of 1 to 2 hours.

Sterilization takes place in the presence of cloud point modifiers such as charged phospholipids.

The cloud point is the temperature at which the surface modifier (surfactant) precipitates out of solution as described above. By the phrase "cloud point modifier" is meant a compound which influences the cloud point of surface modifiers. In particular, the cloud point modifiers useful in the present invention raise the cloud point of the surface modifiers in the compositions. In this way, the surface modifiers do not dissociate from the surface of the nanoparticles at temperatures used in autoclaving. Therefore, nanoparticles thus modified do not agglomerate during the sterilization process, and thus retain their effective average particle sizes of less than about 400 nm after sterilization.

Examples of cloud point modifiers include charged phospholipids. Charged phospholipids include any lipid having a net charge, i.e. any ionic phospholipid with a net positive or negative charge. Examples include such phospholipids as a diacyl-phosphatidyl glycerol, such as the synthetic phospholipid dimyristoyl-phosphatidyl glycerol (DMPG), 1-palmitoyl-2-oleoyl phosphatidyl-serine, DL-alpha-phosphatidyl-L-serine-dipalmitoyl and cardiolipin (diphosphatidyl glycerol). Synthetic phospholipids are typically available in high purity and are relatively stable and physiologically tolerable. A preferred phospholipid is a negatively charged phospholipid, especially DMPG.

The charged phospholipid can be present in an amount of 0.005-20%, preferably 0.01-15%, more preferably 0.05-10%, by weight based on the total weight of the nanoparticle suspension.

Isotonicity refers to the osmotic pressure of a solution. A solution which will be administered into the blood stream of an individual is typically prepared such that the osmotic pressure of that solution is the same as the osmotic pressure of blood. Such a solution is said to be isotonic.

An isotonicity maintaining compound is a compound which provides for the maintenance or alteration of a solution so as to make that solution isotonic. Such an isotonicity maintaining compound will adjust the osmotic pressure of a solution containing the compositions of the present invention so as to provide, or maintain, an isotonic solution.

Exemplary isotonicity maintaining compounds include mannitol, dextrose, sodium chloride, potassium chloride and Ringer's lactate, preferably mannitol and dextrose.

The pH value of a solution to be delivered into the body of a subject is also an important factor. Typically, pH values should not be either too acidic or too basic. To maintain the appropriate pH value of a solution, it is preferable to provide pH value maintaining compounds. These compounds provide a buffering capacity to the solution, to prevent extremes of pH values of the solution upon storage or upon subsequent manipulation.

Exemplary pH value maintaining compounds include the well known buffers such as Tris base, HEPES, carbonate, phosphate, citrate and acetate salts. A preferred buffer is sodium phosphate (either mono- or di-basic, or both).

The composition of the present invention can be further provided with a non-ionic surfactant, preferably poloxamine, after sterilization (such as by autoclaving). The purpose of this additional non-ionic surfactant is to help mask the charges on the surface of the nanoparticles containing phospholipids according to the present invention. Masking these charges imparts longer circulation time for the nanoparticles used in intravenous applications.

This invention further discloses a method of making the nanoparticles having a non-ionic surface modifier adsorbed on the surface and a charged phospholipid cloud point modifier associated therewith. This method involves the preparation of therapeutic or diagnostic nanoparticles, as discussed elsewhere herein, and contacting those nanoparticles with a cloud point modifier. Contacting may be by admixing a suspension of nanoparticles with a solution of cloud point modifier, followed by sterilization at a temperature and for a time sufficient to effect sterilization of the nanoparticle suspension.

The invention will now be illustrated with reference to the following examples but is in no way to be construed as limited thereto.

Example 1. Effect of phospholipids on the particle size of ethyl 3,5-diacetoamido-2,4,6-triiodobenzoate/Tyloxapol nanoparticles.

Samples were prepared according to the following general protocol. 0.001 g each of the tested phospholipids was weighed into an individual 2 ml vial. Then 0.5 ml of ethyl 3,5-diacetoamido-2,4,6-triiodobenzoate/Tyloxapol nanoparticle suspension comprising the diagnostic agent plus the surfactant was then added to each vial. The samples were then sonicated for 15 minutes. Unless otherwise stated, each sample was next autoclaved at 121 °C for 20 minutes. After the samples were cooled, 10 µl of each sample was diluted to 15 ml in Malvern buffer and tested for particle size and zeta potential.

The following phospholipids were tested:

- (a) POPS: 1-Palmitoyl-2-oleyl-phosphatidylserine
- (b) DPPS: Dilpalmitoylphosphatidylserine
- (c) DPPE: Dipalmitoylphosphatidylmonomethylethanolamine
- (d) DMPG: Dimyristoylphosphatidylglycerol
- (e) Cardiolipin

The data are presented in Table 1.

TABLE 1

5 Effect of Phospholipids on the Nanoparticulate
Suspension Upon Autoclaving

Samples in the following study contained 15% ethyl
3,5-diacetoamido-2,4,6-triiodobenzoate and 3% Tyloxapol

10

Additive	Av. Particle Size (nm)	Zeta Potential (mV)
None	159	-6
(not autoclaved)		
0.35% Cardiolipin	162	-28
0.2% POPS	164	-22
0.5% POPS	175	-34
0.2% DPPS	281	-18
0.5% DPPS	266	-20
0.2% DPPE	469	-8
None	202	-6
(not autoclaved)		
0.2% DMPG	235	-20
0.2% Cardiolipin	326	-15
0.2% DPPS	309	-14

40

45

50

55

TABLE 1 contd.

5 Samples in the following study contained 15% ethyl
 3,5-diacetoamido-2,4,6-triiodobenzoate and
 3.5% Tetronic 908.

10	Additive	Av. Particle Size (nm)	Zeta Potential (mV)
15	None (not autoclaved)	173	-0.9
20	0.2% Cardiolipin	367	-4
	0.5% DMPG	490	-26

Example 2. Effect of phospholipids on the particle size of ethyl 3,5-diacetoamido-2,4,6-triiodobenzoate nanoparticles with other surface modifiers.

25 The procedure described in Example 1 was used to examine the effects of the phospholipid DMPG on nanoparticles prepared with surfactants such as T908, DM970 (Rhone-Poulenc), RE960 (Rhone-Poulenc) and CO990 (Rhone-Poulenc). DM970 and CO990 are alkyl phenol ethoxylates. RE960 is an anionic surfactant, i.e. polyethoxylated nonylphenol phosphate. The results of these experiments are shown in
 30 Tables 2 and 3.

35

40

45

50

55

TABLE 2

5 All samples contained 15% ethyl 3,5-diacetoamido-
 2,4,6-triodobenzoate, 0.2% DMPG and 3% of a surfactant
 specified in the first column.

10 Surfactant Avg. Particle Zeta Polydispersity
 Size (nm) Potential
 (mV).

15 Before Autoclaving at 121°C/20 min

None	201	0.16
T-908	174	0.13

20 Autoclaved at 121°C/20 min

None	284	-58	0.20
T-908	502	-39	0.22
DM970	731	-33	0.31
CO990	654	-48	0.29

30 Before Autoclaving at 121°C/20 min

None	238	-52	0.17
T-908	192	-12	0.15
DM970	191	-16	0.16
CO990	190	-38	0.17

40 0.25% Extra DMPG added (total 0.45% DMPG) and
 Autoclaved at 121°C/20 min

None	234	-60	0.13
T-908	477	-37	0.246
DM970	583	-37	0.295
CO990	628	-48	0.248

TABLE 3

All samples contained 15% ethyl 3,5-diacetoamido-2,4,6-triiodobenzoate				
	Excipients	Autoclave Steriliz ⁿ (121 °/20 min)	Av. Size (nm)	Polydispersity
5	0.2% DMPG	no	196	0.14
	0.2% DOSS	no	205	0.15
10	3% DM970, } 10% PEG-400}	no	183	0.21
	3% DM970, } 0.2% DMPG}	no	193	0.18
	0.2% DMPG	yes	709	0.24
	0.5% DMPG	yes	279	0.26
	0.2% DOSS	yes	640	0.27
15	0.5% DOSS	yes	278	0.24
	10% PEG-400	yes	592	0.30
	0.2% RE960	yes	747	0.29

20 Example 3. Effect of various phospholipids on particle size distribution.

The procedure described in Example 1 was used to examine the effects of various phospholipids on nanoparticles. The results of these experiments are shown in Tables 4 and 5.

25

TABLE 4

All samples contained 15% ethyl 3,5-diacetoamido-
2,4,6-triiodobenzoate. Unless otherwise stated, all
samples were autoclaved at 121°C for 20 minutes.

	DMPG	Av. Particle Size (nm)	Polydispersity
35	0.2% (not autoclaved)	196	0.174
40	0.2%	242	0.134
	0.2%	224	0.194
	0.4%	239	0.199
45	0.7%	239	0.187
	1.2%	251	0.193

50

55

TABLE 5

Phospholipid	Autoclave (121 °C/20 min)	Av. Size (nm)	Poly dispersity
None	no	159	0.143
0.5% POPS	yes	174	0.157
0.2% POPS	yes	164	0.137
0.5% DPPS	yes	266	0.137
0.2% DPPS	yes	281	0.141
0.2% DPPE	yes	469	0.135
0.35%	yes	162	0.141
Cardiolipin			

15 Example 4. Effects of various phospholipids on the cloud point of tyloxapol.

Most phospholipids with negative charge raise the cloud point of tyloxapol and stabilize the particle size after 121 °C for 20 minutes. Lipids were weighed directly into a 2 ml vial which was filled to 1 ml with water and bath sonicated to dissolve. The cloud point of 1% tyloxapol with various lipids is shown in Table 6.

20 TABLE 6

Phospholipid	Cloud Point (°C)
none	96
0.1% POPS	>130
0.5% POPS	>130
0.1% DPPS	117
0.1% DPPE	96
0.5% Cardiolipin	120
0.1% Cardiolipin	>130

35 Claims

1. A composition comprising nanoparticles having a non-ionic surfactant as a surface modifier adsorbed on the surface thereof and a charged phospholipid as a cloud point modifier associated therewith, which cloud point modifier is present in an amount sufficient to increase the cloud point of the surface modifier.
2. A composition as claimed in claim 1 wherein said nanoparticles contain a diagnostic or therapeutic agent.
3. A composition as claimed in claim 2 wherein said diagnostic agent is the ethyl ester of diatrazoic acid.
4. A composition as claimed in claim 1 wherein said non-ionic surfactant is selected from the group consisting of a poloxamine and a polymer of the alkyl aryl polyether alcohol type.
5. A composition as claimed in claim 4 wherein said poloxamine is a tetrafunctional block copolymer derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine
6. A composition as claimed in claim 4 wherein said polymer of the alkyl aryl polyether alcohol type is tyloxapol.
7. A composition as claimed in claim 1 wherein said phospholipid is diacylphosphatidyl glycerol.
8. A composition as claimed in claim 1 wherein said phospholipid is dimyristoyl phosphatidyl glycerol.

9. A composition as claimed in any one of the preceding claims further comprising an isotonicity maintaining compound.
10. A composition as claimed in claim 9 wherein said isotonicity maintaining compound is selected from the group consisting of mannitol or dextrose.
5
11. A composition as claimed in any one of the preceding claims further comprising a pH value maintaining compound.
- 10 12. A composition as claimed in claim 11 wherein said pH value maintaining compound is sodium phosphate.
13. A composition as claimed in claim 1 wherein said cloud point modifier increases the cloud point of said surface modifier above the sterilization temperature of the nanoparticles.
15
14. A composition as claimed in claim 13 further comprising a non-ionic surfactant added after sterilization.
15. A composition as claimed in claim 14 wherein said non-ionic surfactant is a poloxamine.
- 20 16. A method of making nanoparticles having a non-ionic surfactant as a surface modifier adsorbed on the surface and a charged phospholipid as a cloud point modifier associated therewith, comprising contacting said nanoparticles with the cloud point modifier for a time and under conditions sufficient to increase the cloud point of the surface modifier.
- 25 17. A method as claimed in claim 16 further comprising the step of sterilizing said nanoparticle.
18. A method as claimed in claim 17 wherein said sterilizing is by steam heat autoclaving.

30

35


40

45

50

55

FIG. 1





(19) Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number: 0 601 618 A3

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 93203045.5

(51) Int. Cl.⁶: A61K 47/48, A61K 9/51,
A61K 49/04

(22) Date of filing: 30.10.93

(33) Priority: 11.12.92 US 989281

(43) Date of publication of application:
15.06.94 Bulletin 94/24

(64) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE

(88) Date of deferred publication of the search report:
02.11.95 Bulletin 95/44

(71) Applicant: EASTMAN KODAK COMPANY
343 State Street
Rochester,
New York 14650 (US)

(72) Inventor: Na, George C., c/o Sterling Winthrop


Inc.
Patent Department,
90 Park Avenue
New York,
New York 10016 (US)
Inventor: Rajagopalan,Natarajan,c/o Sterling
Winthrop Inc.
Patent Department,
90 Park Avenue
New York,
New York 10016 (US)

(74) Representative: Halle, Helen Cynthia et al
Kodak Limited
Patent Department
Headstone Drive
Harrow,
Middlesex HA1 4TY (GB)

(54) Use of charged phospholipids for decreasing nanoparticulate aggregation.

(57) A composition comprising nanoparticles having a non-ionic surfactant as a surface modifier adsorbed on the surface thereof and a charged phospholipid as a cloud point modifier associated therewith, which cloud point modifier is present in an amount sufficient to increase the cloud point of the surface modifier and methods of making such nanoparticles are described. A preferred non-ionic surfactant is a poloxamine or tyloxapol, and a preferred cloud point modifier is dimyristoyl phosphatidyl glycerol.

FIG. 1



EP 0 601 618 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 93 20 3045

DOCUMENTS CONSIDERED TO BE RELEVANT									
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.)						
E	WO-A-94 07940 (ZENECA LTD.) 14 April 1994 * page 4, line 9 - line 17; claims * ---	1	A61K47/48 A61K9/51 A61K49/04						
A	EP-A-0 418 153 (MEDGENIX GROUP S.A.) 20 March 1991 * page 3, line 26 - line 35; claims * ---	1,2,7-12							
A	EP-A-0 270 460 (IRE-CELLTARG S.A.) 8 June 1988 * page 4, line 44 - line 56; example 2 * ---	1,2,7-12							
E	EP-A-0 605 024 (STERLING WINTHROP INC.) 6 July 1994 * page 5, line 47 - line 52; claims * ---	1-18							
E	EP-A-0 602 700 (STERLING WINTHROP INC.) 22 June 1994 * page 5, line 52 - line 56; claims * ---	1-18							
E	EP-A-0 605 024 (IRE CELLTARG SA ODOC CAESAR ACCESSION NUMBER: EP605024) 6 July 1994 * page 3 * * page 5, line 47 - line 52; claims * ---	1-18	TECHNICAL FIELDS SEARCHED (Int.Cl.) A61K						
E	EP-A-0 602 702 (STERLING WINTHROP INC.) 22 June 1994 * column 2, line 51 - column 3, line 40 * * column 7, line 7 - line 21 * -----	1-18							
<p>The present search report has been drawn up for all claims</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td> <td style="width: 33%;">Date of completion of the search</td> <td style="width: 34%;">Examiner</td> </tr> <tr> <td>THE HAGUE</td> <td>5 September 1995</td> <td>Berte, M</td> </tr> </table> <p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons</p> <p>& : member of the same patent family, corresponding document</p>				Place of search	Date of completion of the search	Examiner	THE HAGUE	5 September 1995	Berte, M
Place of search	Date of completion of the search	Examiner							
THE HAGUE	5 September 1995	Berte, M							